What is the future of magnetic nanoparticles in the axillary management of breast cancer? M. AhmedM. Douek Editorial 17 December 2013 Pages: 213 - 218
The effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancer Kathleen M. SturgeonBonnie KyKathryn H. Schmitz Review 14 December 2013 Pages: 219 - 226
Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin Dareen M. AbdelazizLaura S. StoneSvetlana V. Komarova Preclinical Study 11 December 2013 Pages: 227 - 237
Inhibition of LINE-1 retrotransposon-encoded reverse transcriptase modulates the expression of cell differentiation genes in breast cancer cells Radhika PatnalaSung-Hun LeeDanny Rangasamy Preclinical Study Open access 12 December 2013 Pages: 239 - 253
Spinal IFN-γ-induced protein-10 (CXCL10) mediates metastatic breast cancer-induced bone pain by activation of microglia in rat models Huilian BuBin ShuYuke Tian Preclinical study 13 December 2013 Pages: 255 - 263
CXCL13–CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis Subir BiswasSuman SenguptaArindam Bhattacharyya Preclinical study 13 December 2013 Pages: 265 - 276
Hyaluronan synthases (HAS1–3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival Päivi AuvinenKirsi RillaRaija Tammi Preclinical Study 14 December 2013 Pages: 277 - 286
Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo Yunhui HuShuangjing LiDongsheng Xiong Preclinical study 15 December 2013 Pages: 287 - 299
Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells Carolyn A. GoardMichelle Chan-Seng-YueLinda Z. Penn Preclinical study 17 December 2013 Pages: 301 - 312
Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience José Pablo LeoneJulieta LeoneAriel Osvaldo Zwenger Clinical trial 11 December 2013 Pages: 313 - 323
A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure Suleiman MassarwehEdward RomondRichard Elledge Clinical trial 11 December 2013 Pages: 325 - 332
Near-infrared fluorescence sentinel lymph node mapping in breast cancer: a multicenter experience Floris P. R. VerbeekSusan L. TroyanJohn V. Frangioni Clinical Trial 13 December 2013 Pages: 333 - 342
Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS) Julia S. WongYu-Hui ChenJay R. Harris Clinical Trial 18 December 2013 Pages: 343 - 350
A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102 Julie R. GralowWilliam E. BarlowGabriel N. Hortobagyi Clinical trial Open access 19 December 2013 Pages: 351 - 358
Impact of full-field digital mammography on pre-operative diagnosis and surgical treatment of mammographic microcalcification S. M. BundredJ. ZhouN. Bundred Epidemiology 07 December 2013 Pages: 359 - 366
Breast cancer screening of women aged 70–74 years: results from a natural experiment across Australia Carolyn NicksonKate E. MasonAnne M. Kavanagh Epidemiology 11 December 2013 Pages: 367 - 372
Prospective associations of depression with survival: a population-based cohort study in patients with newly diagnosed breast cancer Andrea VodermaierWolfgang LindenRobert Olson Epidemiology Open access 13 December 2013 Pages: 373 - 384
Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women E. TilchT. SeidensG. Chenevix Trench Brief Report 07 December 2013 Pages: 385 - 392
The role of genes co-amplified with nicastrin in breast invasive carcinoma A. SarajlićA. FilipovićN. Pržulj Brief Report 13 December 2013 Pages: 393 - 401
Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers Mitsuya ItohTakayuki IwamotoLajos Pusztai Brief Report 15 December 2013 Pages: 403 - 409